CDTX Insider Trading Activity and SEC Form 4 Filings
CDTX insider trading summary
Over the past 12 months, insiders at Cidara Therapeutics, Inc. (CDTX) reported 1 sale worth $2.2M by 1 insider and no open-market purchases on SEC Form 4. Net insider selling was $2.2M.
Latest CDTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 10, 2025 | Shane Ward | COO & CLO | Sell | $2.2M (9,959 @ $220.08) |
| Sep 11, 2025 | Nicole Negar Davarpanah | Chief Medical Officer | Sell | $30K (474 @ $62.86) |
| Jun 26, 2025 | Rajeev M. Shah | Director | Buy | $100.0M (2,272,727 @ $44.00) |
| Jun 26, 2025 | RA Capital Healthcare Fund LP | Director | Buy | $100.0M (2,272,727 @ $44.00) |
| Jun 26, 2025 | Ra Capital Management, L.P. | Insider | Buy | $100.0M (2,272,727 @ $44.00) |
| Jun 26, 2025 | Peter Kolchinsky | Director | Buy | $100.0M (2,272,727 @ $44.00) |
| Jun 3, 2025 | Chrysa Mineo | Director | Buy | $25K (1,050 @ $23.44) |
| Jun 2, 2025 | Chrysa Mineo | Director | Buy | $49K (2,270 @ $21.71) |
| Mar 11, 2025 | Leslie Tari | Chief Scientific Officer | Sell | $39K (1,773 @ $21.96) |
| Mar 11, 2025 | Shane Ward | COO & CLO | Sell | $37K (1,664 @ $21.96) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.